Anakinra, an IL-1 receptor antagonist, achieved remission in 71% of etoposide-refractory HLH cases without worsening cytopenias [24], while emapalumab’s IFN-γ blockade shows promise in dampening hyperinflammation without compromising antiviral immunity [25]. This evidence concerns the gene IFNG and hemophagocytic syndrome.